One cornerstone of the drug approval process is finding a unique molecular target for a novel compound.Providing this information early on can assist in preventing the pursuit of drug candidates with uninteresting or redundant targets so that precious capital is not allocated to compunds that are unlikely to reach the market. MPM uses a proprietory technology to simplify the process of finding unique and interesting molecular targets . Two assisting application pre-process the data for Normalization and inter-platform tag Conversion.
Chemical Gene takes the next step towards the development of personalized therapies by translating chemical structures into a predicted patter of gene expression profile changes. Chemical Gene is scheduled for release in the fall of 2008.
The core technology matches gene expression profiles for novel drug candidates to profiles of compounds with known molecular targets.